Cipher Pharmaceuticals (TSE:CPH) PT Set at C$12.50 by Canaccord Genuity Group

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) has been assigned a C$12.50 price target by investment analysts at Canaccord Genuity Group in a note issued to investors on Monday,BayStreet.CA reports. The brokerage currently has a “hold” rating on the stock. Canaccord Genuity Group’s price objective points to a potential upside of 11.61% from the company’s current price.

Cipher Pharmaceuticals Trading Down 3.7 %

TSE CPH opened at C$11.20 on Monday. The company has a quick ratio of 2.67, a current ratio of 2.00 and a debt-to-equity ratio of 41.22. The firm has a market cap of C$201.08 million, a PE ratio of 12.37 and a beta of 1.20. The company has a 50 day moving average price of C$12.49 and a 200 day moving average price of C$14.06. Cipher Pharmaceuticals has a 52 week low of C$8.01 and a 52 week high of C$19.69.

Insider Activity

In related news, Director Harold Morton Wolkin sold 3,500 shares of Cipher Pharmaceuticals stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of C$13.49, for a total value of C$47,215.00. Company insiders own 42.00% of the company’s stock.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company’s geographical segments include Canada and the United States.